Literature DB >> 8654136

Raf-1 kinase, epidermal growth factor receptors, and mutant Ras proteins in colonic carcinomas.

S Eggstein1, G Manthey, T Hirsch, F Baas, B U Specht, E H Farthmann.   

Abstract

Epidermal growth factor receptors (EGFR) and ras mutations are known to play a significant role in controlling cell growth and tumor promotion. Both of them transmit mitogenic signals to the nucleus by activation of Raf-1 kinase. In this study, the expression of EGFR and mutant Ras proteins, and, for the first time, the expression, phosphorylation and kinase activity of Raf-1 kinase have been determined in paired samples of colorectal cancer and mucosa. The tumor and mucosa samples did not differ significantly with regard to Raf-1 kinase content and activity. A major difference between tumors and mucosa was found, however, in the phosphorylation of Raf-1. Most of the mucosa samples (13/20), but only 1/20 of the cancer samples, contained hyperphosphorylated Raf-1. EGFR were significantly (p = 0.0025) decreased in the tumors. The decreased phosphorylation of Raf-1 in colonic carcinomas could be the result of activation of Raf-1 phosphatases or inactivation of kinases phosphorylating Raf-1. New forms of treatment based on EGFR overexpression do not seem to be suitable for the majority of colonic cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8654136     DOI: 10.1007/bf02088221

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase.

Authors:  J T Bruder; G Heidecker; U R Rapp
Journal:  Genes Dev       Date:  1992-04       Impact factor: 11.361

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Production of transforming growth factors by human colon cancer lines.

Authors:  R J Coffey; G D Shipley; H L Moses
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

4.  Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon.

Authors:  S V Peña; M F Melhem; A I Meisler; C A Cartwright
Journal:  Gastroenterology       Date:  1995-01       Impact factor: 22.682

5.  Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene.

Authors:  S Untawale; M A Zorbas; C P Hodgson; R J Coffey; G E Gallick; S M North; D M Wildrick; M Olive; M Blick; L C Yeoman
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

6.  Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa.

Authors:  R G Ramsay; M A Thompson; J A Hayman; G Reid; T J Gonda; R H Whitehead
Journal:  Cell Growth Differ       Date:  1992-10

7.  Decreased levels of 1,2-sn-diacylglycerol in human colon tumors.

Authors:  S C Phan; M Morotomi; J G Guillem; P LoGerfo; I B Weinstein
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

8.  Raf-1 protein kinase is required for growth of induced NIH/3T3 cells.

Authors:  W Kolch; G Heidecker; P Lloyd; U R Rapp
Journal:  Nature       Date:  1991-01-31       Impact factor: 49.962

9.  Epidermal growth factor (EGF) stimulates association and kinase activity of Raf-1 with the EGF receptor.

Authors:  H App; R Hazan; A Zilberstein; A Ullrich; J Schlessinger; U Rapp
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

10.  Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue.

Authors:  P G Koenders; W H Peters; T Wobbes; L V Beex; F M Nagengast; T J Benraad
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more
  3 in total

Review 1.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Expression and activity of mitogen activated protein kinases in human colorectal carcinoma.

Authors:  S Eggstein; M Franke; I Kutschka; G Manthey; B U von Specht; G Ruf; E H Farthmann
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

Review 3.  Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer.

Authors:  Jose A García-Sáenz; Javier Sastre; Eduardo Díaz-Rubio García
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.